等待開盤 11-04 09:30:00 美东时间
-0.025
-0.10%
EyePoint, Inc. announced strategic adjustments to reduce operating expenses and focus on its late-stage DURAVYU program for diabetic macular edema (DME) after the Phase 3 LUCIA study in wet AMD did not meet its primary endpoint, despite improvements in vision and treatment burden reduction. The company plans to reduce its workforce by approximately 53% and end wet AMD trials early to conserve capital and prioritize DME development. DURAVYU is exp...
10-19 11:15
EyePoint announced topline results from the LUCIA Phase 3 trial of DURAVYU for wet AMD. While visual improvement was demonstrated, the primary endpoint of statistical non-inferiority in BCVA change vs. aflibercept was not met. Key secondary endpoints were achieved, including a 38% reduction in treatment burden and strong anatomic control. The favorable safety profile was maintained. The DME program remains on track with Phase 3 data expected in Q...
10-19 11:00
Takeda Pharmaceutical Company ($TAK) announced an update on their ongoing clini...
10-02 00:30
Wells Fargo Investment Institute is maintaining a constructive stance on private credit (BIZD) (VPC) (HYIN) (PRIV) and direct lending, citing the asset class's resilience through the first half of 202...
09-09 00:42